GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments

Coverage, in order

1. 2d ago
   
   Medical Xpress indie

   GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments

   Years of research point to obesity and type 2 diabetes raising the risk of developing several types of cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recent medical breakthrough, were originally developed for blood sugar control or diabetes management and also work overtime…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.